Navigation Links
UC Davis bench-to-bedside research: Promising treatment in clinical trials
Date:3/26/2009

DAVIS, CALIF.A new drug developed at the University of California, Davis to treat diabetes, hypertension and inflammatory has entered Phase II of human clinical trials to evaluate its efficacy.

The compound, a soluble epoxide hydrolase enzyme (s-EH) inhibitor, is "a first-in-class drug which may treat a suite of major cardiovascular and metabolic diseases," said entomologist Bruce Hammock, who with UC Berkeley cell biologist Sarjeet Gill discovered the enzyme in 1969 while researching fundamental insect biology.

"This is one of the few examples of basic research in an academic laboratory moving through target validation and compound optimization all the way to the clinic," he said.

The enzyme is involved in the metabolism of arachidonic acid, a key signaling molecule implicated in diabetes, hypertension and inflammatory disorders. "It's an enzyme in the same arachidonic biochemical pathway where many other common pharmaceuticals such as aspirin, Advil, Aleve, Ibuprofen, Motrin and other are active," he said.

Phase 1 evaluated the safety, safe dosage range and side effects of the drug candidate. It then entered Phase IIa.

UC Davis physicians and scientists praised the new drug as promising. Nephrologist and cell biologist Robert Weiss of the UC Davis Health System said the drug could lead to important health implications for patients with type 2 diabetes, a chronic disease affecting an estimated 23.6 million children and adults in the United States.

"Both diabetes and hypertension are often associated with vascular inflammation as is atherosclerosis," Weiss said. "Last year we demonstrated that these compounds dramatically reduce atherosclerosis problem in obese mice."

"These compounds appear useful in a variety of cardiovascular disorders," said biochemist and food scientist Bruce German, UC Davis professor of food science and technology.

"Diabetes and high blood pressure commonly
'/>"/>

Contact: Kathy Keatley Garvey
kegarvey@ucdavis.edu
530-754-6894
University of California - Davis
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. UC Davis research shows that newly discovered drug reduces heart enlargement
2. UC Davis researchers find molecule that targets brain tumors
3. UC Davis discovery offers hope for treating kidney cancer
4. UC Davis team refines cancer treatments to reduce potential nerve damage
5. UC Davis researchers exploring gene therapy to fight AIDS
6. UC Davis researchers discover Achilles heel in pancreatic cancer
7. UC Davis researchers discover a key to aggressive breast cancer
8. UC Davis chemical ecologist wins major award
9. UC Davis researchers discover new drug target for inflammatory disease
10. UC Davis researchers define characteristics, treatment options for XXYY syndrome
11. UC Davis researcher leads climate-change discovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC Davis bench-to-bedside research: Promising treatment in clinical trials
(Date:7/28/2014)... TEMPE, Ariz. - Reactions among minerals and organic compounds ... deep carbon cycle, they provide energy for the deep ... life. However, very little is known about how minerals ... Arizona State University have demonstrated how a common mineral ... negating the need for toxic solvents or expensive ...
(Date:7/28/2014)... School of Medicine have pinpointed a mechanism in part of ... the blood, linking it to both type 1 and type ... issue of Proceedings of the National Academies of Sciences ... located in a part of the hypothalamus known as ... motion that control glucose levels in the blood," said lead ...
(Date:7/28/2014)... wild relative of the domestic tomato, has been published ... headed by Professors Neelima Sinha and Julin Maloof at ... genome information may help breeders produce tastier, more stress-tolerant ... journal Nature Genetics , was lead by Bjrn ... UC Davis labs carried out work on the transcriptome ...
Breaking Biology News(10 mins):Mineral magic? Common mineral capable of making and breaking bonds 2Mineral magic? Common mineral capable of making and breaking bonds 3Glucose 'control switch' in the brain key to both types of diabetes 2
... research in the coming decade. Uppsala University,s entity ... researchers with a powerful system for large-scale compute ... new breakthroughs in research on our public-health disorders. ... technology offers researchers the opportunity to understand the ...
... be due to hereditary cardiac disease. Researchers at the Heidelberg ... to cardiac weakness in an animal model. Just one "false" ... fish have a genetic makeup similar to that of humans, ... Cardiac insufficiency is not just a disease that ...
... to shed new light on HIV,s ability to survive in ... and Infectious Diseases at the NIH has awarded a five-year, ... New York University College of Dentistry to continue its study ... between viruses. The team leader, Dr. David N. Levy, ...
Cached Biology News:Computer superpower strengthens attempts to combat common diseases 2Computer superpower strengthens attempts to combat common diseases 3Why 'lazy Susan' has a weak heart 2NYU College of Dentistry awarded $1.9 million NIH grant for HIV research 2
(Date:7/29/2014)... , July 29, 2014  Discovery Laboratories, Inc. ... advancing a new standard of respiratory critical care, will ... August 5, 2014 before the open of the ... will host a live teleconference and webcast at ... conference call, Discovery Labs, management will discuss the ...
(Date:7/29/2014)... , July 29, 2014  ImmunoClin Corporation ... personalized medicine, treatment of infectious diseases as well ... prognosis and prevention of pathologies like cardiovascular disease, ... 1, 2014, ImmunoClin Corporation will complete the strategic ... Washington, D.C. , a key center of ...
(Date:7/29/2014)... Genera Energy Inc. , ... and supply chain advancements, has announced the deployment ... Grange™ and Supply ASSURE™. Both systems were ... aimed at consolidating and simplifying the entire process, ... and feedstock end users. , “Through the Energy ...
(Date:7/29/2014)... -- United Therapeutics Corporation (NASDAQ: UTHR ... the second quarter ended June 30, 2014. ... medicines are reaching increasing numbers of patients ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... quarter of our extended-release tablet called Orenitram ...
Breaking Biology Technology:Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13
... /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, Inc. ("China Sky One ... a,leading fully integrated pharmaceutical company producing over-the-counter,drugs in the ... approvals from the State Food and Drug Administration (SFDA) ... liniment for pain relief. , ...
... April 23 Idenix Pharmaceuticals, Inc. (Nasdaq: ... and development of drugs for the treatment of human ... C development programs being presented this week at the ... Study of the Liver (EASL) in Copenhagen, Denmark. These ...
... 23 HUNT Biosciences, the,commercial arm of the ... of former GE Healthcare director Per Foss as ... companies with biomarker,discovery and validation services. These are ... past 25 years has gathered blood samples from ...
Cached Biology Technology:China Sky One Medical, Inc. Obtains SFDA Approvals for Geranium Ointment and Musk Liniment for Pain Relief 2China Sky One Medical, Inc. Obtains SFDA Approvals for Geranium Ointment and Musk Liniment for Pain Relief 3Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver 2Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver 3Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver 4Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver 5Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences 2
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
GBL Antibody...
...
... Sequencing Quality 96 Well ... BAC template preparation from 1.5ml ... suitable for automated fluorescent sequencing ... DNA; Utilizes ProPrep strategy which ...
Biology Products: